ReviewMedical oncology (Northwood, London, England)2025
Cell surface vimentin-positive circulating tumor cells: developments, and clinical applications.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic network analysis and functional evidence identify a candidate EMT hub signature associated with nasopharyngeal carcinoma progression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor cells (CTCs) are a vital component of "liquid biopsy," offering significant potential for cancer diagnosis, prognosis, monitoring of treatment response, and studying the mechanisms of metastasis. However, CTCs exhibit considerable heterogeneity, especially those that undergo epithelial-mesenchymal transition (EMT). This process often leads to the downregulation of epithelial markers, such as EpCAM, resulting in their underdetection by conventional methods. Cell surface vimentin (CSV), an emerging marker for cells with a mesenchymal phenotype, presents distinct advantages for the identification and capture of EMT-CTCs. This review provides a comprehensive overview of advancements in research on CSV-positive circulating tumor cells (CSV + CTCs), with a particular focus on their detection technologies, biological functions, and clinical applications.
Indexed as
Identifiers
41329239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.